A phase 1a/1b, open-label, dose-escalation and dose-expansion study of the anti-CTLA-4 monoclonal antibody CS1002 as monotherapy and in combination with anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date19/06/20 → 31/12/23

Keywords

  • Medical Oncology
  • Monoclonal Antibody
  • Clinical trial